Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
This meta-analysis examined the effectiveness of treatments of bipolar depression. Trials were identified using the MEDLINE, EMBASE, http://www.clinicaltrials.gov, and Cochrane databases (1993 to July 2008). The outcome measures included mean change in Montgomery-Asberg Depression Rating Scale (MADRS) or Hamilton Depression Rating Scale (HAM-D) total scores, and rates of response and remission. Overall, 19 publications were included. Medications included quetiapine, lamotrigine, paroxetine, lithium, olanzapine, aripiprazole, phenelzine, and divalproex. The most trials were identified for quetiapine (5) and lamotrigine (6). Not all medications were associated with symptomatic improvement (significant reduction in MADRS/HAM-D total scores vs placebo), with lamotrigine, paroxetine, aripiprazole, and lithium not being different from placebo. Highest reductions in MADRS scores versus placebo were reported for the olanzapine-fluoxetine combination (1 trial: -6.6; 95% confidence interval [CI], -9.59 to -3.61; P = 0.000) and quetiapine monotherapy (5 trials: for 300 mg/d, -4.8; 95% CI, -6.18 to -3.49; P = 0.000; for 600 mg/d, -4.8; 95% CI, -6.22 to -3.28; P = 0.000), with quetiapine monotherapy also showing the highest reduction in HAM-D scores (4 trials: -4.0; 95% CI, -5.0 to -2.9; P = 0.000). All medications except paroxetine, lithium, aripiprazole, and phenelzine significantly improved the ratio of probabilities of response (overall rate, 1.31; 95% CI, 1.22-1.40) and remission (1.32; 95% CI, 1.20-1.45) versus placebo. Variability in efficacy exists between treatments of bipolar depression. Quetiapine and the olanzapine-fluoxetine combination showed the greatest symptomatic improvement. Efficacy considerations will need to be balanced against safety and tolerability of the individual agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243
Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937 · cited 2×
“with bipolar depression.(29) If we are to view bipolar depression separately from unipolar depression, we need to establish which of the current treatment options meet the antidepressant criteria and also whether current treatment guidelines are in line with evidence-based findings.”
BackgroundResultTohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationCalabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
Geddes, J. R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.217 · Cited by 661
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559
Self-citationYoung, A. H., McElroy, S. L., Bauer, M., Philips, N., Chang, W., Olausson, B., Paulsson, B., Brecher, M., & EMBOLDEN I (Trial 001) Investigators (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04995gre · Cited by 390
Self-citationMood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline
Post, R. M., Altshuler, L. L., Leverich, G. S., Frye, M. A., Nolen, W. A., Kupka, R. W., Suppes, T., McElroy, S., Keck, P. E., Denicoff, K. D., et al. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.013045 · Cited by 350 · cited 5×
“AMADRS score of 12 or lower was used by Brown et al,36 Calabrese et al,17 McElroy et al,19 Suppes et al,21 Thase et al,18 Thase et al,37 Tohen et al,38 and Young et al.20 A MADRS score of 10 or lower was used by Muzina et al.39 An Inventory of Depressive Symptoms (IDS) score lower than 12 was used by Frye et al.40 An…”
BackgroundMethodResultInfluential
Research works printed but not linked: 36
- Hirschfeld, 2005, Bipolar disorder-costs and comorbidity., Am J Manag Care, 11, S85
- Kasper, 2003, Issues in the treatment of bipolar disorder., Eur Neuropsychopharmacol, 13, S37, 10.1016/S0924-977X(03)00076-2 · DOI
- Oswald, 2007, Current issues in bipolar disorder: a critical review., Eur Neuropsychopharmacol, 17, 687, 10.1016/j.euroneuro.2007.03.006 · DOI
- Valtonen, 2008, Differences in incidence of suicide attempts during phases of bipolar I and II disorders., Bipolar Disord, 10, 588, 10.1111/j.1399-5618.2007.00553.x · DOI · Paper page
- 2002, Practice guideline for the treatment of patients with bipolar disorder (revision)., Am J Psychiatry, 159, 1
- Goodwin, 2003, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology., J Psychopharmacol, 17, 149, 10.1177/0269881103017002003 · DOI · Paper page
- Yatham, 2009, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009., Bipolar Disord, 11, 225, 10.1111/j.1399-5618.2009.00672.x · DOI · Paper page
- Suppes, 2005, The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder., J Clin Psychiatry, 66, 870, 10.4088/JCP.v66n0710 · DOI · Paper page
- Vieta, 2008, Antidepressants in bipolar depression., Acta Psychiatr Scand, 118, 335, 10.1111/j.1600-0447.2008.01233.x · DOI · Paper page
- Suppes, 2010, Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression., J Affect Disord, 121, 106, 10.1016/j.jad.2009.10.007 · DOI
- Jensen, 2008, N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity., Neuropsychopharmacology, 33, 2303, 10.1038/sj.npp.1301646 · DOI · Paper page
- Yatham, 2005, Atypical antipsychotics in bipolar depression: potential mechanisms of action., J Clin Psychiatry, 66, 40
- Brugue, 2007, Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications., Prog Neuropsychopharmacol Biol Psychiatry, 31, 275, 10.1016/j.pnpbp.2006.06.014 · DOI · Paper page
- Calabrese, 2008, Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials., Bipolar Disord, 10, 323, 10.1111/j.1399-5618.2007.00500.x · DOI · Paper page
- van der Loos, 2009, Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial., J Clin Psychiatry, 70, 223, 10.4088/JCP.08m04152 · DOI · Paper page
- Gijsman, 2004, Antidepressants for bipolar depression: a systematic review of randomized, controlled trials., Am J Psychiatry, 161, 1537, 10.1176/appi.ajp.161.9.1537 · DOI · Paper page
- Gao, 2005, Typical and atypical antipsychotics in bipolar depression., J Clin Psychiatry, 66, 1376, 10.4088/JCP.v66n1106 · DOI
- Harel, 2008, Effectiveness and safety of adjunctive antidepressants in the treatment of bipolar depression: a review., Isr J Psychiatry Relat Sci, 45, 121
- Hamilton, 1960, A rating scale for depression., J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
- Montgomery, 1979, A new depression scale designed to be sensitive to change., Br J Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
- Frye, 2007, A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression., Am J Psychiatry, 164, 1242, 10.1176/appi.ajp.2007.06060981 · DOI · Paper page
- Vieta, 2002, A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers., J Clin Psychiatry, 63, 508, 10.4088/JCP.v63n0607 · DOI · Paper page
- Higgins, 2002, Quantifying heterogeneity in a meta-analysis., Stat Med, 21, 1539, 10.1002/sim.1186 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses., BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Agosti, 2007, Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression., Int Clin Psychopharmacol, 22, 309, 10.1097/YIC.0b013e3280c28410 · DOI
- Goldsmith, 2004, Spotlight on lamotrigine in bipolar disorder., CNS Drugs, 18, 63, 10.2165/00023210-200418010-00007 · DOI
- Nemeroff, 2001, Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression., Am J Psychiatry, 158, 906, 10.1176/appi.ajp.158.6.906 · DOI · Paper page
- Silverstone, 2001, Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial., Acta Psychiatr Scand, 104, 104, 10.1034/j.1600-0447.2001.00240.x · DOI · Paper page
- Goodnick, 2007, Bipolar depression: a review of randomised clinical trials., Expert Opin Pharmacother, 8, 13, 10.1517/14656566.8.1.13 · DOI
- Kemp, 2008, Bipolar depression: trial-based insights to guide patient care., Dialogues Clin Neurosci, 10, 181, 10.31887/DCNS.2008.10.2/dekemp · DOI
- Silverstone, 2004, A review of acute treatments for bipolar depression., Int Clin Psychopharmacol, 19, 113, 10.1097/00004850-200405000-00001 · DOI
- Perlis, 2006, Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial., J Clin Psychiatry, 67, 1747, 10.4088/JCP.v67n1112 · DOI · Paper page
- Martinez-Aran, 2008, Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change., Bipolar Disord, 10, 566, 10.1111/j.1399-5618.2008.00611.x · DOI
- Tohen, 2009, The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders., Bipolar Disord, 11, 453, 10.1111/j.1399-5618.2009.00726.x · DOI · Paper page
- Vieta, 2007, Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study., Bipolar Disord, 9, 413, 10.1111/j.1399-5618.2007.00479.x · DOI · Paper page
- Baptista, 2004, The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management., Metab Syndr Relat Disord, 2, 290, 10.1089/met.2004.2.290 · DOI · Paper page
Cited by
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710
Self-citationYatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013
Ferrari, A. J., Stockings, E., Khoo, J., Erskine, H. E., Degenhardt, L., Vos, T., & Whiteford, H. A. (2016) · Bipolar Disorders · doi:10.1111/bdi.12423 · Cited by 583
Potential Mechanisms of Action of Lithium in Bipolar Disorder: Current Understanding
Malhi, G. S., Tanious, M., Das, P., Coulston, C. M., & Berk, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0039-0 · Cited by 453
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Metadata
- Authors
- Vieta, E., Locklear, J., Günther, O., Ekman, M., Miltenburger, C., Chatterton, M. L., Åström, M., & Paulsson, B.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2010-10
- Volume
- 30
- Issue
- 5
- Pages
- 579-590
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2047612847
- Cited by
- 119
- References
- 16
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181f15849
- The paper
- Vieta, E., Locklear, J., Günther, O., Ekman, M., Miltenburger, C., Chatterton, M. L., Åström, M., & Paulsson, B. (2010). Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181f15849
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.